Navigation Links
Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
Date:10/27/2009

Bio-activated Prodrug Demonstrates Significant Reduction in Incidence of GI Ulcers and Erosions

SAN DIEGO, Oct. 27 /PRNewswire/ -- Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions. In the study, subjects receiving LT-NS001 experienced a 78 percent reduction in the rate of gastric ulcers, and fewer gastric and duodenal erosions, when compared with subjects receiving Naprosyn(®) (naproxen). The LT-NS001 prodrug is unique among non-steroidal anti-inflammatory drugs (NSAIDs) as it is pharmacologically inactive as a COX inhibitor in the GI tract, but once absorbed into the bloodstream, it is converted rapidly to naproxen. LT-NS001 has been engineered to reduce the GI safety risks associated with NSAIDs. Results were announced here at the American College of Gastroenterology's (ACG) Annual Scientific Meeting and presented by Jay L. Goldstein, MD, FACG, Professor of Medicine at the University of Illinois at Chicago, who was the lead investigator for the study.

"The positive results of this study challenge the conventional wisdom regarding NSAID-induced gastrointestinal injury, which physicians generally believe can be driven by systemic exposure to the drug. This study demonstrates that a novel mechanism for NSAID therapy, namely a bio-activated prodrug technology, can provide a significant level of improvement in GI safety, and that may be surprising to many physicians," said Peter A. Lankau, Chief Executive Officer of Logical Therapeutics. "This study brings us one step closer to fulfilling a significant unmet medical need for an NSAID with an improved GI toxicity profile and we look forward to continuing the clinical development of LT
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... 8 Cost reductions offset a recession-driven ... AHPI ) narrowly back into profitability in the second ... quarter ended December 31, 2009 declined almost ... the same quarter last year to $11.4 million ... sales were reduced even more sharply, from approximately ...
(Date:2/8/2010)... N.J. , Feb. 8 Savient ... the company will release financial results for the fourth ... market on Thursday, February 25, 2010 . ... Group Vice President and Chief Financial Officer, will host ... a.m. Eastern Time on February 26, 2010 ...
(Date:2/8/2010)... BETHESDA, Md. , Feb. 8 Hanger ... that it plans to report its results of operations for ... Wednesday, February 10, 2010 . ,, The Company plans to ... ended December 31, 2009 on Wednesday, February ... conference call is scheduled to begin at 9:00 a.m., ...
Breaking Medicine Technology:Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call 2Diabetes cases to double and costs to triple by 2034 62179 1Diabetes cases to double and costs to triple by 2034 62179 2Diabetes cases to double and costs to triple by 2034 62179 3Nanowires key to future transistors electronics 14983 1Nanowires key to future transistors electronics 14983 2Nanowires key to future transistors electronics 14983 3Research sheds light on workings of anti cancer drug 62178 1Research sheds light on workings of anti cancer drug 62178 2Research sheds light on workings of anti cancer drug 62178 3
(Date:2/9/2010)... television drama may be more effective in persuading young ... on the same issue, according to a new study. ... televised drama about a teen pregnancy felt more vulnerable ... to more support for using birth control. , However, ... caused by teen pregnancies were unmoved, and had no ...
(Date:2/9/2010)... from a large-scale study of key antimalarial medicines ... high percentage of medicines circulating on national markets ... to the growth of drug-resistant strains of ... malaria. The findings, released today by the Promoting ... program implemented by the US Pharmacopeial Convention (USP), ...
(Date:2/9/2010)... , Feb. 9 The following ... Blackwell : ,, "Reversing the childhood obesity epidemic will ... Michelle Obama demonstrated today. ,, "As the ... schools loaded with chips and soda -- and few ... however, that bleak food landscape extends far beyond the ...
(Date:2/9/2010)... WEST PALM BEACH, Fla. , Feb. 9 /PRNewswire-USNewswire/ ... a grant awarded to the School District of Palm ... eat right and get fit. The Robert Wood Johnson Foundation ... opportunities for physical activity and access to affordable healthy foods ... and Palm Springs communities. Based on a rigorous ...
(Date:2/9/2010)... iPhone application created by UH researchers is providing ... world. Those annual rankings of America,s fattest and ... host of indirect indicators may soon have a ... the University of Houston provides objective data. , ... from Apple,s "App Store," allows users to keep ...
Breaking Medicine News(10 mins):Health News:TV drama can be more persuasive than news program, study finds 2Health News:TV drama can be more persuasive than news program, study finds 3Health News:TV drama can be more persuasive than news program, study finds 4Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 2Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 3Health News:Planting Seeds to Fight Childhood Obesity 2Health News:Phone app providing real-time statistics on physical activity around the world 2Health News:Phone app providing real-time statistics on physical activity around the world 3
... for Occupation Health and Safety Development says that women who ... cancer. Citing a study by US-based Fred Hutchinson Cancer Research ... up work in the graveyard shift - usually from 6 ... usually done at call centers placed them at a high ...
... now found to play a role in reversing the aging ... new age spots in women. ,A team of ... stable n-acetyl glucosamine have shown to reduce the melanin content ... damage treatment. ,For many women, accumulated sun exposure ...
... have uncovered that missing portions of 2 chromosomes located at ... ,The senior author Walter J. Curran Jr., M.D., ... of Thomas Jefferson University in Philadelphia, have found a paradigm ... known as gliomas. ,Reporting last week in the ...
... Glaxo Kline has found to be effective in preventing cervical ... (HPVs). ,Researchers suggested that HPV vaccination were ... the subjects. ,In the past 20 years, advances ... discovery of the link between HPV and cervical cancer. Two ...
... dietary restrictions, ensuring that no gluten, a product found in ... this may soon come to an end. Researchers in the ... food processing -- AN-PEP -- may be able to break ... intestine. This information could be vital because the small intestine ...
... of Radiotherapy and Oncology of the All-India Institute of ... stating that her ad hoc appointment was terminated due ... Institute recently. ,In a letter to Anbumani ... Dr. Ajita Gill said that although the "vicious ...
Other Medicine News:Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 3Health News:Missing Chromosomes Revealed Brain Tumor Therapy Effect – Research Find 2Health News:Missing Chromosomes Revealed Brain Tumor Therapy Effect – Research Find 3Health News:Celiac Disease Sufferers See an End to their Misery 2
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: